What Katadolon Forte Treats: Main Uses and Benefits

Katadolon forte may be considered for symptomatic management in situations involving certain distressing symptoms, and is relevant for easing symptoms associated with acute or episodic changes in adults.

The use of this medication is typically reserved for cases where other common analgesic options are not appropriate.

The medication is relevant in contexts marked by increased discomfort or tension, commonly including symptoms related to physical discomfort in the musculoskeletal system and other symptoms of increased neurological or muscular activity. It is used for managing symptom clusters that may become intense or disruptive, applicable in conditions presenting with systemic or localized discomfort.

In these symptomatic episodes, the medication is applied in clinical settings that involve unstable symptom patterns, offering short-term supportive relief that assists with easing the overall symptom load. This approach supports general well-being during symptomatic phases and is relevant when short-term symptom stabilization is generally needed.

Quick Fact: Relief for Acute Discomfort
This medication is considered relevant to help address pronounced symptoms associated with acute episodes, assisting with maintaining functional stability when symptoms interfere with daily functioning.

Regulatory References

1. European Medicines Agency (EMA) on Flupirtine

Official Population Eligibility and Constraints

Katadolon forte (Flupirtine maleate) is subject to strict regulatory constraints defining patient eligibility. Use is primarily restricted to adults for the management of acute pain, and only when treatment with other standard analgesics (such as NSAIDs or weak opioids) is officially contraindicated. The treatment period for all eligible patients must not exceed two weeks.

Absolute Contraindications

The medicine is contraindicated and must not be used by several patient populations. These absolute exclusions include individuals with pre-existing liver disease or any risk of developing hepatic encephalopathy. Use is also prohibited for patients with myasthenia gravis, cholestasis, chronic alcoholism, or known hypersensitivity to the drug.

Age and Condition Restrictions

For age-related eligibility, the medicine is not recommended for use in children or adolescents under 18 years, as safety and efficacy have not been established. Specific conditional use applies to certain populations: older adults and patients with renal impairment require an official dose reduction.

Regarding reproductive status, safety is not established during pregnancy, and breastfeeding must be stopped if the medicine is indicated during lactation.

Interactions with other medicines and products

The official regulatory profile for Katadolon forte (Flupirtine) is primarily structured around the risk of liver injury and central nervous system effects.

Interaction Classifications (Regulatory Basis)

The most stringent interaction classification is the formal prohibition of co-administration with other medicinal products known to cause drug-induced liver injury (hepatotoxic drugs). This restriction is explicitly mandated to prevent a cumulative increase in the risk of severe hepatic damage, a primary concern identified in European regulatory reviews. Use is also contraindicated in populations with pre-existing liver disease or chronic alcoholism.

Interaction Type	Interacting Substance/Category	Restriction / Monitoring Requirement
Hepatotoxic Risk	Other Hepatotoxic Drugs	Formally Prohibited Combination.
	Acetaminophen (Paracetamol)	Requires monitoring of hepatic transaminase levels.
Pharmacodynamic	Alcohol and Other Sedatives	Concurrent use may potentiate central effects (tiredness, dizziness).
Exposure/Toxicity	Oral Anticoagulants (e.g., Warfarin)	Requires monitoring of coagulation parameters (Prothrombin Time).

The regulatory documentation identifies that co-administration with oral anticoagulants, such as Warfarin, may increase the potential for the anticoagulant's toxicity, necessitating specific laboratory monitoring. Furthermore, a pharmacodynamic interaction exists with alcohol and other sedative-type medications, which may lead to additive central nervous system depressant effects. These requirements establish which combinations are prohibited and which require mandatory procedural constraints as defined by regulatory authorities.

Katadolon forte exerts its action through a dual pharmacodynamic mechanism that modulates neurotransmission in the central nervous system.

Its primary action involves the non-competitive antagonism of the N-methyl-D-aspartate (NMDA) receptor, a key subtype of glutamate receptor. By binding to a site distinct from the agonist binding site, the compound reduces the flow of positive ions through the channel, thereby modulating the glutamatergic system. This activity decreases neuronal hyperexcitability and reduces central nervous system sensitization.

The compound also functions as a selective blocker of neuronal N-type voltage-gated calcium channels (Cav2.2). The block of these presynaptic channels limits calcium influx required for vesicular fusion, which in turn reduces the exocytotic release of excitatory neurotransmitters from the nerve terminal. These concurrent mechanistic interactions collectively modulate afferent signal transmission.

Official Administration Guidelines for Flupirtine Maleate

Katadolon forte, which contains the active substance flupirtine maleate, is subject to specific usage instructions. These guidelines define the method, frequency, duration, and dosing adjustments for its administration.

Dosing and Administration Schedule

Administration Scope	Instruction
Route of Administration	Primarily oral (capsules/tablets). Other forms include rectal (suppositories) or intramuscular injection.
Standard Dosing Pattern	Immediate-Release (IR) forms are typically dosed 3 to 4 times daily. Modified-Release (MR) forms, such as 400 mg strength, are scheduled for once-daily intake.
Maximum Daily Dose	The total dose of flupirtine maleate should not exceed 600 mg per day.
Duration of Treatment	The maximum duration of treatment must not exceed 2 weeks for all oral and suppository formulations.
Timing for Intake	Oral formulations, particularly the MR tablets, are generally recommended to be taken after meals with a sufficient quantity of water.

---

Population-Specific Dosing Rules

Specific dose modifications are required for certain populations to maintain safe use:

• Elderly Patients (aged 65 years and over) and Patients with Renal/Hepatic Impairment: The daily dose must be reduced by 50% to a maximum of 300 mg per day.
• Pediatric Population: The medication is not recommended for use in children and adolescents under the age of 18 years, as safety and efficacy have not been established.

Patients should be treated with the lowest effective dose for the shortest possible duration, and the 2-week limit must be strictly observed.

Research evidence / Overview of studies for Katadolon forte

---

Evidence for use in Acute, Short-Term Pain Relief

The primary research base for Katadolon forte involves Randomized Controlled Trials (RCTs) and systematic reviews that were used in studies examining symptom intensity or variability during acute pain episodes. These studies were applied in research contexts involving fluctuating or unstable symptoms, such as post-operative discomfort or conditions associated with acute or disruptive episodes. Research examined adult populations and was designed to monitor patient-reported outcomes describing perceived discomfort. Studies report how symptoms evolved in the observed populations by monitoring changes in pain intensity scales and documenting the use of supplemental pain medication.

Despite the existence of a consistent body of data for short-term use, the evidence is limited regarding the outcomes observed beyond the typical short study windows. Long-term effects are not fully established, and the research provides limited insight into whether its evaluation for acute pain was associated with subsequent development of chronic symptoms.

---

Research Status for Chronic Pain Conditions

Katadolon forte was also evaluated in studies that focused on conditions characterized by fluctuating or episodic manifestations over longer periods, such as chronic musculoskeletal discomfort. The evidence base included uncontrolled, long-term observational studies that monitored outcomes related to systemic or functional imbalance. Regulatory reviews found that research exploring the medication's use in long-lasting chronic pain conditions was associated with limited evidence and did not meet required criteria.

The evidence for this application is limited, as the majority of supporting data came from studies that were uncontrolled (meaning they lacked a comparison group like placebo), which is a key research limitation. Ultimately, the evidence for this indication was considered insufficient by regulators.

---

Key Gaps and Remaining Research Uncertainties

The research base has several known research limitation frames. A primary concern noted in regulatory reviews is the limited follow-up duration across the research base. Furthermore, evidence quality varies across studies, with some older trials having an unclear risk of bias in reporting. The evidence highlights what is known — and what is still uncertain, emphasizing that data for certain groups remain insufficient and that long-term effects are not fully established.

Key Studies & References

1. Flupirtine-containing medicines: Article 31 referral Public Assessment Report (European Medicines Agency)

Common questions about Katadolon forte (FAQ)

---

Q: What is the active substance in Katadolon forte?

According to the official product information, flupirtine maleate is the active substance in Katadolon forte. This substance is responsible for the medicinal effects described in the official labeling.

---

Q: What kind of pain is Katadolon forte used to treat?

Official information indicates that Katadolon forte is authorized for the treatment of acute pain in adults. Regulatory labeling indicates that its use is restricted to cases where other pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs) or weak opioid analgesics, are contraindicated.

---

Q: How long is the treatment with Katadolon forte usually recommended for?

Regulatory documents state that treatment with Katadolon forte is generally authorized for a maximum duration of two weeks. The drug's use is specifically intended to be short-term for managing acute pain episodes.

---

Q: Does Katadolon forte have a potential effect on the liver?

Official product information emphasizes that Katadolon forte has been associated with a risk of serious liver injury. The product label states that due to this risk, liver function monitoring is required during treatment, and the drug is contraindicated in individuals with pre-existing liver disease.

---

Q: What is the mechanism of action of flupirtine, the active substance?

Flupirtine is classified as a Selective Neuronal Potassium Channel Opener (SNEPCO). The regulatory description of the mechanism indicates that it influences pain signals by stabilizing the neuronal membrane potential, thus reducing the excitability of nerve cells involved in pain transmission.

---

Q: Can Katadolon forte cause dependency or addiction?

Official information indicates that flupirtine, the active substance, has not been associated with the development of dependency or addiction. It is not classified as an opioid, and its mechanism is different from that of narcotic painkillers.

---

Q: Is Katadolon forte an opioid or a non-steroidal anti-inflammatory drug (NSAID)?

Regulatory documents clarify that Katadolon forte, which contains flupirtine, is neither an opioid nor a non-steroidal anti-inflammatory drug (NSAID). It belongs to a different class of pain relievers known as non-opioid central analgesics, possessing a unique mechanism of action.

Katadolon forte (flupirtine maleate) must be stored and handled according to specific official requirements to maintain its stability and ensure safety.

Storage Requirements

• Temperature: The product must be stored at a temperature not exceeding 30, C.
• Protection: The medicine must be protected from light and moisture and should be stored in a cool, dry place.
• Child Safety: It is a mandatory requirement that the medication be kept strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Katadolon forte must be disposed of in a responsible manner. The official regulatory guidance states that the medicine must not be thrown away via wastewater or household trash. Patients should follow local regulatory guidelines for medicine disposal, often by taking the product to a pharmacy or designated take-back program for pharmaceutical waste.